HIV-infected children are a special patient group


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

It is necessary to regularly assess the possibility of switching to a new regimen reducing the risk of toxicity, to simplify antiretroviral therapy (ART), to facilitate medication adherence, and to enhance the efficiency of treatment in HIV-infected children with achieved suppression on current ART. When there is a need for lifetime therapy, the toxicity of ART is at the forefront. Numerous studies have revealed that metabolic disorders occur in 26-65% of children and are not dependent upon either the duration of ART or the age of a child. Along with high efficiency, therapy adherence is also important for children: daily single-tablet regimens are of undoubted benefit since they increase the adherence by 15-25% compared to the separate use of drugs. The rilpivirine/tenofovir/emtricitabine (RPV/TDF/FTC) single-tablet regimen used in HIV-infected adolescents is accompanied by sustained virological suppression and improved metabolic status. Metabolically favorable regimens with the minimum multiplicity and frequency of drug use should be chosen for HIV-infected children and adolescents throughout treatment in order to achieve its high efficiency, adherence, and safety.

Full Text

Restricted Access

About the authors

E. E Voronin

Republican Clinical Infectious Diseases Hospital, Ministry of Health of Russia

Email: kibsekretar@yandex.ru
MD, Infectiologist of the Highest Qualification Category; Chief Physician, Chief Freelance Specialist un HIV Diagnosis and Treatment, Ministry of Health of Russia Ust-Izhora Settlement, Saint Petersburg, Russia

I. B Latysheva

Republican Clinical Infectious Diseases Hospital, Ministry of Health of Russia

Email: kibsekretar@yandex.ru
Cand. Med. Sci., Infectiologist of the Highest Qualification Category; Deputy Chief Physician for Organization and Methodology 3, Shlisselburgskoe Shosse, Ust-Izhora, Saint Petersburg 196645, Russia Telephone: +7(812)464-93-29

C. Mussini

University of Modena and Reggio Emilia

Email: kibsekretar@yandex.ru
Head, Department of Infectious Diseases and Tropical Medicine; Associate Professor, Department of Infectious Diseases Modena, Italy

References

  1. Fortuny C., Deya-Martinez A., Chiappini E., Galli L., de Martino M., Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr. Infect. Dis. J. 2015; 34(5, Suppl 1): S36-43. http://www.ncbi.nlm.nih.gov/pubmed/25629891.
  2. Falcon-Neyra L., Palladino C., Navarro Gomez M.L. et al. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. Medicine (Baltimore). 2016; 95(24): e3842. https://www. ncbi.nlm.nih.gov/pubmed/27310962.
  3. Mollan K.R., Smurzynski M., Eron J.J., Daar E.S., Campbell T.B., Sax P.E., Gulick R.M., Na L., O’Keefe L., Robertson K.R., Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann. Intern. Med. 2014; 161(1): 1-10. doi: 10.7326/M14-0293
  4. Sheng-Li Li, Peng Xu, Lei Zhang, Gui-Xiang Sun, Zhao-Jun Lu. Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis. HIV Clin. Trials. 2014; 15(6): 261-8. doi: 10.1310/hct1506-261.
  5. Bangsberg D.R., Ragland K., Monk A., Deeks S.G. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24(18): 2835-40.
  6. Sax P.E., Meyers J.L., Mugavero M., Davis K.L. Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitali zation among Commercially Insured HIV Patients in the Unite d States. PLoS One 2012; 7(2): e31591. doi: 10.1371/journal. pone.0031591.
  7. Sutton S.S., Hardin J.W., Bramley T.J., D’Souza A.O., Bennett C.L. Single-versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am. J. Manag. Care 2016; 22(4): 242-8.
  8. Sutton S.S., Magagnoli J., Hardin J.W. Odds ofViral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy. Pharmacotherapy 2017; 37(2): 204-13. DOI: 10.1002/ phar.1889.
  9. EACS Guidelines, 9.0, 2017. European AIDS Clinical Society. https://eacs-editors.sanfordguide.com/
  10. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition. June 2016. http:// www.who.int/hiv/pub/arv/arv-2016/en/11
  11. Airoldi M., Zaccarelli M., Bisi L., Bini T., Antinori A., Mussini C., Bai F., Orofino G., Sighinolfi L., Gori A., Suter F., Maggiolo F. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer. Adherence 2010; 13: 115-https://doi.org/10.2147/PPA.S10330
  12. Antinori A., Angeletti C., Ammassari A., Sangiorgi D., Giannetti A., Buda S., Girardi E., Esposti L.D. Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study. J. Int. AIDS Soc. 2012; 15(Suppl 4): 18098. DOI: 10.7448/ ias.15.6.18098.
  13. Molina J.M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
  14. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-37.
  15. Cohen C., Wohl D., Arribas J.R., Wohl D., Arribas J.R., Henry K., Van Lunzen J., Bloch M., Towner W., Wilkins E., Ebrahimi R., Porter D., White K., Walker I., Chuck S., De-Oertel Sh., Fralich T. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28: 989-97.
  16. Palella F.J., Fisher M., Tebas P., Gazzard B., Ruane P., Van Lunzen J., Shamblaw D., Flamm J., Ebrahimi R., Porter., White K., Hindman J., Elbert E., De-Oertel S., Fralich T. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28: 335-44. DOI: 10.1097/ QAD.0000000000000087
  17. Lombard J., Bunupuradah T., Flynn P.M., Ramapura m J., Ssali F., Crauwels H., Hoogstoel A., Van Eygen V., Stevens M. Rilpivirine as a Treatment for HIV-infected Antiretroviral-naive Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. Pediatr. Infect. Dis. J. 2016; 35(11): 1215-21.
  18. Jantarabenjakul W., Anugulruengkitt S., Kasipong N., Thammajaruk N. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. Antivir. Ther. 2017 (10). doi: 10.3851/IMP3198.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies